MA34806B1 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques

Info

Publication number
MA34806B1
MA34806B1 MA35945A MA35945A MA34806B1 MA 34806 B1 MA34806 B1 MA 34806B1 MA 35945 A MA35945 A MA 35945A MA 35945 A MA35945 A MA 35945A MA 34806 B1 MA34806 B1 MA 34806B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
quinolin
methyl
formula
therapeutic compound
Prior art date
Application number
MA35945A
Other languages
English (en)
Inventor
Yu Cao
Wolfgang Hackl
Ping Li
Shoufeng Li
Tahseen Mirza
Hartmut Zehender
Jiahao Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45346568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34806(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34806B1 publication Critical patent/MA34806B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour l'administration orale d'un composé thérapeutique de formule (I), qui comprend les éléments suivants : des granules comportant au moins un composé thérapeutique de formule (I) (voir ci-dessous), en particulier 2-méthyl-2-[4-(3-méthyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phényl]
MA35945A 2010-12-03 2011-12-01 Compositions pharmaceutiques MA34806B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41953810P 2010-12-03 2010-12-03
US201161436324P 2011-01-26 2011-01-26
PCT/US2011/062837 WO2012075253A2 (fr) 2010-12-03 2011-12-01 Compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
MA34806B1 true MA34806B1 (fr) 2014-01-02

Family

ID=45346568

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35945A MA34806B1 (fr) 2010-12-03 2011-12-01 Compositions pharmaceutiques

Country Status (21)

Country Link
US (1) US20130245061A1 (fr)
EP (1) EP2645999A2 (fr)
JP (1) JP2013544845A (fr)
KR (1) KR20140010009A (fr)
CN (1) CN103237544A (fr)
AR (1) AR084067A1 (fr)
AU (1) AU2011336478A1 (fr)
CA (1) CA2817618A1 (fr)
CL (1) CL2013001557A1 (fr)
CO (1) CO6801722A2 (fr)
EC (1) ECSP13012654A (fr)
GT (1) GT201300144A (fr)
MA (1) MA34806B1 (fr)
MX (1) MX2013006187A (fr)
NZ (1) NZ610467A (fr)
PE (1) PE20140792A1 (fr)
RU (1) RU2013130224A (fr)
SG (1) SG190210A1 (fr)
TW (1) TW201304779A (fr)
WO (1) WO2012075253A2 (fr)
ZA (1) ZA201303223B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192367A1 (fr) * 2012-06-22 2013-12-27 Novartis Ag Traitement d'une tumeur neuroendocrine
CN104661652B (zh) * 2012-09-27 2018-08-28 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
WO2016155884A1 (fr) 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylquinoléines et leur utilisation comme inhibiteurs des kinases atm
AU2016263176A1 (en) 2015-05-20 2017-12-07 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
WO2018096402A1 (fr) 2016-11-23 2018-05-31 Novartis Ag Méthodes d'amélioration de la réponse immunitaire à l'évérolimus, au dactolisib ou aux deux
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
JP2022543803A (ja) * 2019-08-07 2022-10-14 アクリプス ワン インコーポレイテッド （６ａＳ）－６－メチル－５，６，６ａ，７－テトラヒドロ－４Ｈ－ジベンゾ［ｄｅ，ｇ］キノリン－１０，１１－ジオールの医薬組成物
US20230070369A1 (en) * 2019-12-20 2023-03-09 Intervet Inc. Pyrazole pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
RU2006121646A (ru) * 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20080125477A1 (en) * 2006-05-16 2008-05-29 Decode Genetics, Ehf. 7-(acryloyl) indole compositions and methods of making and using same
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
US20100016449A1 (en) * 2006-12-21 2010-01-21 Boehringer Ingelheim International Gmbh Formulations with Improved Bioavailability
KR101472607B1 (ko) * 2007-02-20 2014-12-15 노파르티스 아게 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린

Also Published As

Publication number Publication date
KR20140010009A (ko) 2014-01-23
TW201304779A (zh) 2013-02-01
WO2012075253A2 (fr) 2012-06-07
US20130245061A1 (en) 2013-09-19
AR084067A1 (es) 2013-04-17
MX2013006187A (es) 2013-07-15
ECSP13012654A (es) 2013-08-30
WO2012075253A3 (fr) 2012-08-09
EP2645999A2 (fr) 2013-10-09
ZA201303223B (en) 2014-01-29
PE20140792A1 (es) 2014-07-09
AU2011336478A1 (en) 2013-06-06
CL2013001557A1 (es) 2013-10-25
CA2817618A1 (fr) 2012-06-07
CN103237544A (zh) 2013-08-07
JP2013544845A (ja) 2013-12-19
GT201300144A (es) 2014-06-09
RU2013130224A (ru) 2015-01-10
SG190210A1 (en) 2013-06-28
CO6801722A2 (es) 2013-11-29
NZ610467A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
MA34806B1 (fr) Compositions pharmaceutiques
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
WO2009069032A3 (fr) Nouveaux agonistes des récepteurs des glucocorticoïdes
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
MX2013001805A (es) Derivados de 2-(arilamino)-3h-imidazo [4,5-b] piridina-6-carboxamida y su uso como inhibidores de mpges-1.
UA106199C2 (ru) Производные аминобензамида как агенты, пригодные для использования для борьбы с паразитами животных
MA32904B1 (fr) Composes de purine
MY151295A (en) Pyrimidyl indoline compound
GEP20135806B (en) Lactams as beta secretase inhibitors
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
WO2011006935A3 (fr) Dérivés de tétrazole
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2012128582A3 (fr) Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
SE0303480D0 (sv) Benzofuranes
PT1981862E (pt) Compostos relacionados com lantionina para o tratamento de doenças inflamatórias
WO2009034432A8 (fr) Nouveaux composés actifs utilisés comme antagonistes des récepteurs muscariniques
DE602007005387D1 (de) Ptors
JO2820B1 (en) Combination of refined thiazolium salt or a primary compound and artemisinin or a derivative thereof to treat serious malaria cases